AIM
TPST icon

Acrospire Investment Management’s Tempest Therapeutics TPST Stock Holding History

Acrospire Investment Management’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3
Closed -$18K – 2536
2017
Q1 		$18K Sell
3
-5
-63% -$23.3K 0.01% 1673
2016
Q4 		$36K Buy
+8
New +$99.7K 0.01% 1562

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acrospire Investment Management's TPST Position: Q2 2017 in Review

Acrospire Investment Management sold out of Tempest Therapeutics (TPST) in Q2 2017, closing a stake of 3 shares — an estimated $18K sold.

Acrospire Investment Management first reported a position in TPST in Q4 2016 and held it in 2 quarters. The position peaked at $36K in Q4 2016. 54 funds tracked by Wall St. Rank hold TPST as of Q2 2017.

  • Acrospire Investment Management reported no remaining Tempest Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 3 Tempest Therapeutics shares in Q2 2017, an estimated $18K.
  • Acrospire Investment Management first reported a position in Tempest Therapeutics in Q4 2016 and held it in 2 quarters.
  • Acrospire Investment Management's Tempest Therapeutics position peaked at $36K in Q4 2016.
  • 54 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.